Salute e Benessere

AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023

AC Immuneto Present at the BTIG Virtual Biotechnology Conference2023Lausanne, Switzerland,July28 ,2023– AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will participate in a Fireside chat and one-on-one investor meetings during the BTIG Virtual Biotechnology Conference 2023, taking place on August 7-8, 2023.During the Fireside chat, Dr...
Nasdaq GlobeNewswire
28/07/2023

HANQUYOU Marks 3rd Anniversary with Brilliant Achievements

Henlius has aggressively pursued overseas commercialization of HANQUYOU, collaborating with global partners such as Accord, Abbott, Cipla, Eurofarma, Elea, the Jacobson Group, and KG Bio to bring its therapeutics to patients in major biopharmaceutical markets in the U.S., Europe, likewise emerging markets. As of now, HANQUYOU (Zercepac®) has been launched in approximately 20 European countries. Moreover, Henlius further expanded its overseas presence in 2022, with the launch of HANQUYOU in…
PR Newswire
28/07/2023

Curium Receives Marketing Authorization in the EU for PYLCLARI™, an Innovative…

18 F) formerly known as ( 18 F)-DCFPyL) indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings: Primary staging of patients with high-risk PCa prior to initial curative therapyTo localize recurrence of PCa in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with...
Nasdaq GlobeNewswire
28/07/2023

ALLCLEAR SURVEY: COST-OF-LIVING CUTBACKS TO HOLIDAY SPENDING PUTS HOLIDAYMAKERS…

Where people are most likely to be making cutbacksThe AllClear data indicates that the most common holiday cutbacks comprise of: switching to a cheaper airline (40%); only taking essential items (34%); using public transport rather than taxis (30%); opting for self-catering (26%) and eating out rather than going half-board (26%). Where people are most likely to be making cutbacksThe AllClear data indicates that the most common holiday cutbacks comprise of: switching to a cheaper airline...
PR Newswire
28/07/2023

Press Release: Sanofi to acquire Qunol®, a fast-growing U.S. brand in the…

Sanofi to acquireQunol ®,a fast-growing U.S. brand in the healthy aging segmentTransaction brings Qunol ®, a trusted, profitable double-digit growth and market-leading brand in health & wellness to Sanofi's CHC U.S. portfolio Addition of Qunol's CoQ10 and Turmeric products strengthens Sanofi's CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the U.S.Paris, July28 , 2023. Sanofi...
Nasdaq GlobeNewswire
28/07/2023

Groupe Casino: Conciliation proceedings: Casino Group enters into an agreement…

Conciliation proceedings: Casino Group enters into an agreement in principle with EPGC a.s ., Fimalac , Attestor and some of its main creditorsUpdate of 2023 forward-looking items Paris, 28 July 2023Casino Group announces that it has, under the aegis of the conciliators and of theComitéInterministériel de restructuration industrielle (CIRI), entered into an agreement in principle on 27 July 2023 with EP Global Commerce a.s., Fimalac, Attestor...
Nasdaq GlobeNewswire
28/07/2023

Press Release: Solid Q2 performance and strong pipeline momentum, Full-year 2023…

Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raisedParis, July 28, 2023Q2 2023 sales growth of 3.3% at CER and business EPS (1)growth of 8.1% at CERSpecialty Care grew 11.8% driven by Dupixent ®(€2,562 million, +34.2%) and Nexviazyme ®(€103 million, +146.5%) more than offsetting anticipated impact of Aubagio ®generic competition in the U.S.Vaccines up 9.1% due to strong PPH vaccines sales in Rest of World region and...
Nasdaq GlobeNewswire
28/07/2023

BPEA EQT to acquire a majority stake in Indira IVF - India's largest chain of…

India is one of the fastest growing markets globally for Assisted Reproductive Technology services and significantly underpenetrated compared to more developed markets. Infertility rates in India are estimated to be around 15 percent and they are expected to rise, driven by lifestyle changes, such as poor diets, stress levels and pollution. Today, India completes around 300,000 IVF cycles annually, and over the next decade, the number of cycles done across the country is expected to grow around…
PR Newswire
28/07/2023

WuXi Vaccines' First Drug Substance Facility in China Released for GMP…

Mr. Jian Dong, CEO of WuXi Vaccines, commented, "The release of the drug substance facility at our Suzhou site and the start of manufacturing marks a major milestone for WuXi Vaccines. Leveraging our expertise, advanced facilities, and innovative technology platforms, while adhering to global cGMP standards and regulatory guidelines, we are primed to meet the rising demand for vaccine development and manufacture, and advance the availability of safe and effective vaccines worldwide."…
PR Newswire
28/07/2023

Genmab Updates 2023 Financial Guidance

Company Announcement COPENHAGEN , Denmark; July 28 , 2023 – Genmab A/S(Nasdaq:GMAB) announced today its preliminaryfirst half 2023 financial results and its updated2023 financial guidance. PreliminaryFirst Half 2023 Financial Results In the first half of 2023, Genmab's revenue increased by 34% and operating profit increased by 10%, compared to the first half of 2022 primarily due to higher product royalties. Operating expenses increased by 45%,...
Nasdaq GlobeNewswire
28/07/2023

TraceLink Accelerates DSCSA 2023 Customer Readiness, Supply Chain…

Key highlights of the quarter include: Key highlights of the quarter include: Speaking about why Sentara Health chose TraceLink as their DSCSA compliance partner,Tyler Martinson, Pharmacy Manager at Sentara Health, had this to say: "TraceLink was vital to this role, their support, both their IT and just their knowledge of the law. Laws change and rules keep coming out and it was very helpful to have someone who was really focused on that to help explain to us what was coming down the...
PR Newswire
27/07/2023

Publication Relating to a Transparency Notification

REGULATED INFORMATIONPublication Relating to a Transparency NotificationMont-Saint-Guibert(Belgium),July 27 , 2023 ,10.30pm CET / 4.30pm ET –In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a rectification of an earlier transparency notification.On July 25, 2023, Nyxoah received the rectification of the April 16,...
Nasdaq GlobeNewswire
27/07/2023

Nyxoah to Participate in the 43rd Canaccord Genuity Growth Conference

Nyxoah to Participate in the 43rdCanaccord Genuity GrowthConferenceMont-Saint-Guibert, Belgium – July 27 , 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Canaccord Genuity 43 rdGrowth Conference, which takes place August 7...
Nasdaq GlobeNewswire
27/07/2023

Nyxoah to Release Second Quarter 2023 Financial Results on August 8, 2023

Nyxoah to Release Second Quarter 2023Financial Resultson August 8 , 2023Mont-Saint-Guibert, Belgium –July 27 , 2023 , 10:30pm CET / 4:30pmET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results...
Nasdaq GlobeNewswire
27/07/2023

Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023

The announcement will be followed by an investor conference call and webcast on Friday, August 4, 2023 at 8:00 am ET / 2:00 pm CET. The call will include the Company's second quarter results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: 1-877-451-6152International: 1-201-389-0879Conference ID: 13739252Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1619596&tp_key=40e9fac8fcAbout Cellectis Cellectis is...
Nasdaq GlobeNewswire
27/07/2023

Information on the Total Number of Voting Rights and Shares

REGULATED INFORMATION Information on the Total Number of Voting Rights and SharesMont-Saint-Guibert(Belgium),July 27 , 2023 ,10:30 pmCET / 4:30pm ET–In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 4,924,151.05Total number of securities carrying voting rights:...
Nasdaq GlobeNewswire
27/07/2023

PHAXIAM Therapeutics announces a reverse share split of its shares

PRESS RELEASE PHAXIAM Therapeutics announces a reverse share split of its shares Reverse share split by the exchange of ten (10) existing shares with a par value of ten-euro cents (€0.10) for one (1) new share with a par value of one euro (€1)Publication of the reverse share split notice in the BALO: July 31 st, 2023Start of the reverse share split: August 16 th, 2023Effective date of the reverse share split (listing of new shares): September 18 th...
Nasdaq GlobeNewswire
27/07/2023

World Hepatitis Alliance raise awareness of viral hepatitis on World Hepatitis…

A recent survey2 from WHA found that nearly half (42%) of people globally are unaware that one of the leading causes of liver cancer is viral hepatitis. Nearly three quarters (74%) of those surveyed say knowing hepatitis causes liver cancer means they are more likely to get tested and over four fifths (82%) say they are more likely to get vaccinated. A recent survey 2from WHA found that nearly half (42%) of people globally are unaware that one of the leading causes of liver cancer is viral…
PR Newswire
27/07/2023

Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and…

Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million 2, and long-term deposit at €9.3 million 3as of June 30, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectivelyRevenues of €1.9 m in H1 2023, compared to €0.1 million for the same period in 2022 Daix (France), Long Island City (New York, United States), July 27, 2023– Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage...
Nasdaq GlobeNewswire
27/07/2023

EssilorLuxottica: Publication of the 2023 Interim Financial Report

Publication of the 2023 Interim Financial Report Charenton-le-Pont, France(July , 27 2023–6:30 pm)– The Board of Directors of EssilorLuxottica met on July 25, 2023 to approve the condensed consolidated interim financial statements for the six-month period ended June 30, 2023.EssilorLuxottica's 2023 Interim Financial Report has been published today. The Interim Financial Report comprises the First-half 2023 Management Report, the Condensed...
Nasdaq GlobeNewswire
27/07/2023

Ipsen S.A. publishes its 2023 Half-Year Financial Report

Ipsen S.A. publishes its 2023 Half-Year Financial Report Attachment 2023 Half-year Financial Report
Nasdaq GlobeNewswire
27/07/2023

EssilorLuxottica and Kodak Announce Perpetual Worldwide Brand License…

EssilorLuxottica and Kodak Announce Perpetual WorldwideBrandLicense AgreementCharenton-le-Pont, France and Rochester, New York (July 27, 2023)– EssilorLuxottica and Eastman Kodak Company announced today that they have signed a perpetual worldwide license agreement granting EssilorLuxottica the exclusive right to use the Kodak registered trademarks for products and services in connection with EssilorLuxottica's business.Effective January 1,...
Nasdaq GlobeNewswire
27/07/2023

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating…

LONDON and NEW YORK, July27, 2023(GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Operating Officer. Mr Clementi will formally take up the COO role effective September 1, 2023. Mr. Clementi's extensive experience...
Nasdaq GlobeNewswire
27/07/2023

Enzyme Replacement Therapy Market is estimated to be US$ 16.94 billion by 2030…

Enzyme replacement therapy is used for replacing a deficient enzyme in an individual who is suffering with inherited enzyme deficiency syndrome. Further, the deficient enzyme is replaced by infusion of enzyme which is purified from animal or human blood/tissues. Enzyme replacement therapy is used for replacing a deficient enzyme in an individual who is suffering with inherited enzyme deficiency syndrome. Further, the deficient enzyme is replaced by infusion of enzyme which is purified from...
PR Newswire
27/07/2023
Altri  Comunicati